This page has been archived on the Web
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.
"Control-Max," an unauthorized product sold for sexual enhancement, may pose serious health risks
- Starting date:
- December 9, 2016
- Type of communication:
- Advisory
- Subcategory:
- Drugs
- Source of recall:
- Health Canada
- Identification number:
- RA-61378
- Issue
- What you should do
- Who is affected
- Background
- Media enquiries
- Public enquiries
- What Health Canada is doing
- Images
Issue
Health Canada is advising Canadians that the unauthorized product “Control-Max” may pose serious health risks as it is labelled to contain a prescription drug (yohimbine). The product was being sold online by the company RGR Canada Inc.
What you should do
- Stop using this product. Consult with your health care professional if you have used this product and have health concerns.
- Read product labels to verify that health products have been authorized for sale by Health Canada. Authorized health products have an eight-digit DIN, DIN-HM or NPN. You can also check if products have been authorized for sale by searching Health Canada’s Drug Product Database and Licensed Natural Health Product Database.
- Report adverse events to health products to Health Canada by calling toll-free at 1-866-234-2345, or by reporting online, by mail or by fax.
Who is affected
Consumers who have bought or used the product.
Affected product
Control-Max
Background
Yohimbine is a prescription drug and should be used only under the supervision of a health care professional. The use of drugs containing yohimbine (either as yohimbine hydrochloride or yohimbe bark extract) may result in serious adverse reactions, particularly in people with high blood pressure, or heart, kidney or liver disease. Side effects associated with yohimbine include increased blood pressure and heart rate, anxiety, dizziness, tremors, headache, nausea and sleep disorders. It should not be used by children, or pregnant or nursing women.
Media enquiries
Health Canada
(613) 957-2983
Public enquiries
(613) 957-2991
1-866 225-0709
What Health Canada is doing
Health Canada has requested RGR Canada Inc. to recall the product. Health Canada will take additional action if necessary to prevent further sale of this product in Canada.
Images
Select thumbnail to enlarge - opens in a new window
